In a retrospective study of EORTC-22033 randomized phase III trial samples, MGMT promoter methylation was revealed to have predictive value in IDH-mutant grade II glioma treated with TMZ, but the cutoff value used in that study was dramatically higher than that commonly used in IDH-wildtype GBM30. This evidence concerns the gene MGMT and central nervous system cancer.